Status:
ACTIVE_NOT_RECRUITING
Staph Intervention for Effective Local Defense
Lead Sponsor:
Johns Hopkins Bloomberg School of Public Health
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Staphylococcus Aureus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The ...
Detailed Description
Staphylococcus aureus (SA) is a common cause of skin and soft tissue infections (SSTI) and invasive infections in the United States (US). Infections caused by methicillin-resistant SA (MRSA) are of pa...
Eligibility Criteria
Inclusion
- Native American adult living on or adjacent to the WMA Tribal lands
- 18 years of age and older
- Lab-confirmed SA carriage at time of enrollment
- Ability to provide written informed consent
- Ability to comply with follow-up activities
- Risk factor for SA-associated infection: Diagnosed with diabetes OR body mass index ≥30 OR documented SSTI or SA infection in the past 3 years
Exclusion
- Immediate family member of study staff
- Allergy to citrus or any ingredient in Nozin, Hibiclens, or mupirocin
- Without a permanent home (e.g., living in a group home, shelter, or is unhoused)
- Use of antibiotics within 30 days prior to the first study visit (time-limited)
- Current SA infection (time-limited)
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2026
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06210594
Start Date
April 1 2024
End Date
January 1 2026
Last Update
December 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Whiteriver Center for Indigenous Health
Whiteriver, Arizona, United States, 85941